Nicholas Walla, MD in Worcester, MA - Medicare Student in an Organized Health Care Education/Training Program

Nicholas Walla, MD is a medicare enrolled "Student In An Organized Health Care Education/training Program" physician in Worcester, Massachusetts. His current practice location is 55 Lake Ave N, Worcester, Massachusetts. You can reach out to his office (for appointments etc.) via phone at (508) 334-1000.

Nicholas Walla is licensed to practice in * (Not Available) (license number ) and he also participates in the medicare program. He does not accept medicare assignments directly but he may accept medicare through third-party (refer to Reassignment section below) and may also prescribe medicare part D drugs. His NPI Number is 1154818607.

Contact Information

	Nicholas Walla, MD
	55 Lake Ave N, Worcester, MA 01655-0002
	(508) 334-1000
	Not Available

Physician's Profile

Full Name	Nicholas Walla
Gender	Male
Speciality	Student In An Organized Health Care Education/training Program
Location	55 Lake Ave N, Worcester, Massachusetts
Accepts Medicare Assignments	Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs.

NPI Data:

NPI Number: 1154818607
Provider Enumeration Date: 04/20/2018
Last Update Date: 03/25/2024

Medicare PECOS Information:

PECOS PAC ID: 3678927902
Enrollment ID: I20230920003294

Medical Identifiers

Medical identifiers for Nicholas Walla such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1154818607	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
207X00000X	Orthopaedic Surgery	35.140803 (Ohio)	Secondary
390200000X	Student In An Organized Health Care Education/training Program	(* (Not Available))	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Nicholas Walla is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Nicholas Walla, MD 6480 Harrison Ave Ste 201, Cincinnati, OH 45247-7961 Ph: (513) 713-1779	Nicholas Walla, MD 55 Lake Ave N, Worcester, MA 01655-0002 Ph: (508) 334-1000

News Archive

Study examines complications in adult tonsillectomies and impact on health care expenditures

A study released today of 36,210 adult tonsillectomy patients finds that 20 percent will have a complication, offering valuable new insights to a decades long discussion. The study, featured in the April 2014 issue of Otolaryngology-Head and Neck Surgery, examines the prevalence of complications in adult tonsillectomies and the impact on health care expenditures.

BioLineRx's BL-1020 Phase IIb EAGLE trial data on schizophrenia to be presented at ECSR

BioLineRx, a biopharmaceutical development company, today announced that data from the successfully completed Phase IIb EAGLE study of BL-1020, a first in class GABA-enhanced antipsychotic for the treatment of schizophrenia, will be presented at the 3rd European Conference on Schizophrenia Research (ECSR) held in Berlin, Germany.

Transforming biomedical research to develop TB vaccines

In the past decade, scientists have made significant progress building the critical knowledge and infrastructure needed to identify and develop novel tuberculosis (TB) vaccine candidates and move the most promising ones into human clinical trials. The results of those trials, coupled with advances from other TB studies, have paved the way for the next 10 years of research on TB vaccines, a critical component of TB control efforts, note scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

Biogen and Eisai announce results of LTE Phase 1b study of aducanumab for treating MCI

Biogen and Eisai Co., Ltd. announced results from a recent analysis of the ongoing long-term extension Phase 1b study of aducanumab, an investigational treatment for mild cognitive impairment due to Alzheimer's disease and mild AD dementia.

Analyzing the health law's 'prognosis'

As experts continue to parse the specifics of a federal Judge's Monday ruling striking down the health overhaul, experts speculate about what the Supreme Court could decide. Meanwhile, insurers, health industry stakeholders and even state officials mull their next steps.

Nicholas Walla, MD - Medicare Student in an Organized Health Care Education/Training Program in Worcester, MA